Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 RevolKa Signs Master Service Agreement with Daiichi Sankyo | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

RevolKa Signs Master Service Agreement with Daiichi Sankyo

Will create and deliver functional proteins in collaboration with Daiichi Sankyo by using its protein engineering platform technology.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

RevolKa Ltd., a venture-backed biotech company providing a protein engineering technology platform, has signed a master service agreement with Daiichi Sankyo Co., Ltd., under which RevolKa will create and deliver highly functional proteins in collaboration with Daiichi Sankyo Co., Ltd. by using its proprietary protein engineering platform technology, called aiProtein
 
RevolKa’s proprietary technology, aiProtein is a directed protein evolution technology integrated with artificial intelligence (AI). Its AI engine is trained with sequence-function relationship data to statistically predict sequences for an evolved protein function. Furthermore, aiProtein can evolve more than two functions simultaneously. This technology is a powerful and cost-effective tool for the creation of novel and highly-optimized proteins for pharmaceutical and industrial uses.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics